161 related articles for article (PubMed ID: 36056084)
41. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
42. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
43. Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines.
Zhang S; Liu J; Lu ZY; Xue YT; Mu XR; Liu Y; Cao J; Li ZY; Li F; Xu KL; Wu QY
Cell Oncol (Dordr); 2022 Oct; 45(5):1005-1018. PubMed ID: 36036884
[TBL] [Abstract][Full Text] [Related]
44. A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
Massacci G; Venafra V; Latini S; Bica V; Pugliese GM; Graziosi S; Klingelhuber F; Krahmer N; Fischer T; Mougiakakos D; Boettcher M; Perfetto L; Sacco F
Leukemia; 2023 Feb; 37(2):288-297. PubMed ID: 36509894
[TBL] [Abstract][Full Text] [Related]
45. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
[TBL] [Abstract][Full Text] [Related]
46. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
47. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
48. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
49. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Smith CC; Levis MJ; Perl AE; Hill JE; Rosales M; Bahceci E
Blood Adv; 2022 Apr; 6(7):2144-2155. PubMed ID: 35130342
[TBL] [Abstract][Full Text] [Related]
50. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
51. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
52. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
Chang YT; Hernandez D; Alonso S; Gao M; Su M; Ghiaur G; Levis MJ; Jones RJ
Blood Adv; 2019 Mar; 3(6):908-916. PubMed ID: 30898762
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
54. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
55. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
56. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
57. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
Piloto O; Wright M; Brown P; Kim KT; Levis M; Small D
Blood; 2007 Feb; 109(4):1643-52. PubMed ID: 17047150
[TBL] [Abstract][Full Text] [Related]
58. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
59. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
[TBL] [Abstract][Full Text] [Related]
60. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]